Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

MicroRNA Dysregulation and Non-Muscle-Invasive Bladder Cancer Prognosis.

Andrew AS, Karagas MR, Schroeck FR, Marsit CJ, Schned AR, Pettus JR, Armstrong DA, Seigne JD.

Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):782-788. doi: 10.1158/1055-9965.EPI-18-0884. Epub 2019 Jan 30.

PMID:
30700445
2.

RE: Elevated Bladder Cancer in Northern New England: The Role of Drinking Water and Arsenic.

Koutros S, Lenz P, Hewitt SM, Kida M, Jones M, Schned AR, Baris D, Pfeiffer R, Schwenn M, Johnson A, Karagas MR, Garcia-Closas M, Rothman N, Moore LE, Silverman DT.

J Natl Cancer Inst. 2018 Nov 1;110(11):1273-1274. doi: 10.1093/jnci/djy045. No abstract available.

3.

Comparative study of separation between ex vivo prostatic malignant and benign tissue using electrical impedance spectroscopy and electrical impedance tomography.

Murphy EK, Mahara A, Khan S, Hyams ES, Schned AR, Pettus J, Halter RJ.

Physiol Meas. 2017 Jun;38(6):1242-1261. doi: 10.1088/1361-6579/aa660e. Epub 2017 Mar 10.

4.

VISTA Deficiency Accelerates the Development of Fatal Murine Lupus Nephritis.

Ceeraz S, Sergent PA, Plummer SF, Schned AR, Pechenick D, Burns CM, Noelle RJ.

Arthritis Rheumatol. 2017 Apr;69(4):814-825. doi: 10.1002/art.40020.

5.

Prostate Cancer Detection Using Composite Impedance Metric.

Khan S, Mahara A, Hyams ES, Schned AR, Halter RJ.

IEEE Trans Med Imaging. 2016 Dec;35(12):2513-2523. Epub 2016 Jun 9.

6.

A single-centre experience with tumour tract seeding associated with needle manipulation of renal cell carcinomas.

Viswanathan A, Ingimarsson JP, Seigne JD, Schned AR.

Can Urol Assoc J. 2015 Nov-Dec;9(11-12):E890-3. doi: 10.5489/cuaj.3278. Epub 2015 Dec 14.

7.

MicroRNA molecular profiling from matched tumor and bio-fluids in bladder cancer.

Armstrong DA, Green BB, Seigne JD, Schned AR, Marsit CJ.

Mol Cancer. 2015 Nov 14;14:194. doi: 10.1186/s12943-015-0466-2.

8.

3D Microendoscopic Electrical Impedance Tomography for Margin Assessment During Robot-Assisted Laparoscopic Prostatectomy.

Mahara A, Khan S, Murphy EK, Schned AR, Hyams ES, Halter RJ.

IEEE Trans Med Imaging. 2015 Jul;34(7):1590-1601. doi: 10.1109/TMI.2015.2407833. Epub 2015 Feb 27.

PMID:
25730825
9.

Expression of tumor suppressive microRNA-34a is associated with a reduced risk of bladder cancer recurrence.

Andrew AS, Marsit CJ, Schned AR, Seigne JD, Kelsey KT, Moore JH, Perreard L, Karagas MR, Sempere LF.

Int J Cancer. 2015 Sep 1;137(5):1158-66. doi: 10.1002/ijc.29413. Epub 2015 Feb 25.

10.

Ovarian strumal carcinoid producing peptide YY associated with severe constipation: a case report and review of the literature.

Muller KE, Tafe LJ, Gonzalez JL, West LA, Schned AR.

Int J Gynecol Pathol. 2015 Jan;34(1):30-5. doi: 10.1097/PGP.0000000000000117. Review.

PMID:
25473750
11.

Genetic polymorphisms modify bladder cancer recurrence and survival in a USA population-based prognostic study.

Andrew AS, Gui J, Hu T, Wyszynski A, Marsit CJ, Kelsey KT, Schned AR, Tanyos SA, Pendleton EM, Ekstrom RM, Li Z, Zens MS, Borsuk M, Moore JH, Karagas MR.

BJU Int. 2015 Feb;115(2):238-47. doi: 10.1111/bju.12641. Epub 2014 Mar 26.

12.

Body mass and smoking are modifiable risk factors for recurrent bladder cancer.

Wyszynski A, Tanyos SA, Rees JR, Marsit CJ, Kelsey KT, Schned AR, Pendleton EM, Celaya MO, Zens MS, Karagas MR, Andrew AS.

Cancer. 2014 Feb 1;120(3):408-14. doi: 10.1002/cncr.28394. Epub 2013 Oct 10.

13.

Electrical property sensing biopsy needle for prostate cancer detection.

Mishra V, Schned AR, Hartov A, Heaney JA, Seigne J, Halter RJ.

Prostate. 2013 Nov;73(15):1603-13. doi: 10.1002/pros.22695. Epub 2013 Sep 2.

PMID:
23996675
14.

HSD3B and gene-gene interactions in a pathway-based analysis of genetic susceptibility to bladder cancer.

Andrew AS, Hu T, Gu J, Gui J, Ye Y, Marsit CJ, Kelsey KT, Schned AR, Tanyos SA, Pendleton EM, Mason RA, Morlock EV, Zens MS, Li Z, Moore JH, Wu X, Karagas MR.

PLoS One. 2012;7(12):e51301. doi: 10.1371/journal.pone.0051301. Epub 2012 Dec 19.

15.

Genetic variant as a selection marker for anti-prostate stem cell antigen immunotherapy of bladder cancer.

Kohaar I, Porter-Gill P, Lenz P, Fu YP, Mumy A, Tang W, Apolo AB, Rothman N, Baris D, Schned AR, Ylaya K, Schwenn M, Johnson A, Jones M, Kida M, Silverman DT, Hewitt SM, Moore LE, Prokunina-Olsson L.

J Natl Cancer Inst. 2013 Jan 2;105(1):69-73. doi: 10.1093/jnci/djs458. Epub 2012 Dec 23.

16.

The diaphragms of fenestrated endothelia: gatekeepers of vascular permeability and blood composition.

Stan RV, Tse D, Deharvengt SJ, Smits NC, Xu Y, Luciano MR, McGarry CL, Buitendijk M, Nemani KV, Elgueta R, Kobayashi T, Shipman SL, Moodie KL, Daghlian CP, Ernst PA, Lee HK, Suriawinata AA, Schned AR, Longnecker DS, Fiering SN, Noelle RJ, Gimi B, Shworak NW, Carrière C.

Dev Cell. 2012 Dec 11;23(6):1203-18. doi: 10.1016/j.devcel.2012.11.003.

17.

Ureteroscopic biopsy of upper tract urothelial carcinoma using a novel ureteroscopic biopsy forceps.

Wason SE, Seigne JD, Schned AR, Pais VM Jr.

Can J Urol. 2012 Dec;19(6):6560-5.

PMID:
23228292
18.

Cell-cycle control in urothelial carcinoma: large-scale tissue array analysis of tumor tissue from Maine and Vermont.

Lenz P, Pfeiffer R, Baris D, Schned AR, Takikita M, Poscablo MC, Schwenn M, Johnson A, Jones M, Kida M, Cantor KP, Rothman N, Silverman DT, Hewitt SM, Moore LE.

Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1555-64. doi: 10.1158/1055-9965.EPI-12-0261. Epub 2012 Jul 3.

19.

Correlation of LINE-1 methylation levels in patient-matched buffy coat, serum, buccal cell, and bladder tumor tissue DNA samples.

van Bemmel D, Lenz P, Liao LM, Baris D, Sternberg LR, Warner A, Johnson A, Jones M, Kida M, Schwenn M, Schned AR, Silverman DT, Rothman N, Moore LE.

Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1143-8. doi: 10.1158/1055-9965.EPI-11-1030. Epub 2012 Apr 26.

20.

Analysis of the Distribution and Temporal Trends of Grade and Stage in Urothelial Bladder Cancer in Northern New England from 1994 to 2004.

Schned AR, Lenz P, Moore LE, Johnson A, Jones M, Kida M, Silverman DT, Schwenn M, Kelsey KT, Andrew AS, Baris D, Karagas MR.

ISRN Pathol. 2012;2012. pii: 283670.

21.

Smiling glomerulus reveals diagnosis in seronegative anti-glomerular basement membrane disease.

Neild GH, Sedlacek M, Tracy SA, Schned AR.

NDT Plus. 2011 Oct;4(5):352. doi: 10.1093/ndtplus/sfr056. Epub 2011 May 4. No abstract available.

22.

Intake of α-linolenic acid and other fatty acids in relation to the risk of bladder cancer: results from the New Hampshire case-control study.

Brinkman MT, Karagas MR, Zens MS, Schned AR, Reulen RC, Zeegers MP.

Br J Nutr. 2011 Oct;106(7):1070-7. doi: 10.1017/S0007114511001346. Epub 2011 May 10.

23.

Association of secondhand smoke exposures with DNA methylation in bladder carcinomas.

Wilhelm-Benartzi CS, Christensen BC, Koestler DC, Houseman EA, Schned AR, Karagas MR, Kelsey KT, Marsit CJ.

Cancer Causes Control. 2011 Aug;22(8):1205-13. doi: 10.1007/s10552-011-9788-6. Epub 2011 Jun 10.

24.

Passive bioelectrical properties for assessing high- and low-grade prostate adenocarcinoma.

Halter RJ, Schned AR, Heaney JA, Hartov A.

Prostate. 2011 Dec;71(16):1759-67. doi: 10.1002/pros.21393. Epub 2011 Apr 25.

PMID:
21520155
25.

GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis.

Moore LE, Baris DR, Figueroa JD, Garcia-Closas M, Karagas MR, Schwenn MR, Johnson AT, Lubin JH, Hein DW, Dagnall CL, Colt JS, Kida M, Jones MA, Schned AR, Cherala SS, Chanock SJ, Cantor KP, Silverman DT, Rothman N.

Carcinogenesis. 2011 Feb;32(2):182-9. doi: 10.1093/carcin/bgq223. Epub 2010 Oct 29.

26.

Identification of methylated genes associated with aggressive bladder cancer.

Marsit CJ, Houseman EA, Christensen BC, Gagne L, Wrensch MR, Nelson HH, Wiemels J, Zheng S, Wiencke JK, Andrew AS, Schned AR, Karagas MR, Kelsey KT.

PLoS One. 2010 Aug 23;5(8):e12334. doi: 10.1371/journal.pone.0012334.

27.

DNA methylation profiles delineate etiologic heterogeneity and clinically important subgroups of bladder cancer.

Wilhelm-Benartzi CS, Koestler DC, Houseman EA, Christensen BC, Wiencke JK, Schned AR, Karagas MR, Kelsey KT, Marsit CJ.

Carcinogenesis. 2010 Nov;31(11):1972-6. doi: 10.1093/carcin/bgq178. Epub 2010 Aug 28.

28.

Implications of LINE1 methylation for bladder cancer risk in women.

Wilhelm CS, Kelsey KT, Butler R, Plaza S, Gagne L, Zens MS, Andrew AS, Morris S, Nelson HH, Schned AR, Karagas MR, Marsit CJ.

Clin Cancer Res. 2010 Mar 1;16(5):1682-9. doi: 10.1158/1078-0432.CCR-09-2983. Epub 2010 Feb 23.

29.

Stromal lipofuscinosis of the seminal vesicle.

Schned AR, Brennick JB, Gonzalez JL.

Pathology. 2010 Feb;42(2):177-9. doi: 10.3109/00313020903493963. No abstract available.

PMID:
20085522
30.

Best cases from the AFIP: testicular seminoma with lymph node metastases.

Krohmer SJ, McNulty NJ, Schned AR.

Radiographics. 2009 Nov;29(7):2177-83. doi: 10.1148/rg.297085241. No abstract available.

PMID:
19926769
31.

Arsenic exposure predicts bladder cancer survival in a US population.

Kwong RC, Karagas MR, Kelsey KT, Mason RA, Tanyos SA, Schned AR, Marsit CJ, Andrew AS.

World J Urol. 2010 Aug;28(4):487-92. doi: 10.1007/s00345-009-0477-y. Epub 2009 Oct 16.

32.

Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.

Schwaab T, Schwarzer A, Wolf B, Crocenzi TS, Seigne JD, Crosby NA, Cole BF, Fisher JL, Uhlenhake JC, Mellinger D, Foster C, Szczepiorkowski ZM, Webber SM, Schned AR, Harris RD, Barth RJ Jr, Heaney JA, Noelle RJ, Ernstoff MS.

Clin Cancer Res. 2009 Aug 1;15(15):4986-92. doi: 10.1158/1078-0432.CCR-08-3240. Epub 2009 Jul 21.

33.

Pseudolipomatosis in hysteroscopically resected tissues from the gynecologic tract: pathologic description and frequency.

Unger ZM, Gonzalez JL, Hanissian PD, Schned AR.

Am J Surg Pathol. 2009 Aug;33(8):1187-90. doi: 10.1097/PAS.0b013e3181a0d3a6.

PMID:
19440147
34.

DNA repair genotype interacts with arsenic exposure to increase bladder cancer risk.

Andrew AS, Mason RA, Kelsey KT, Schned AR, Marsit CJ, Nelson HH, Karagas MR.

Toxicol Lett. 2009 May 22;187(1):10-4. doi: 10.1016/j.toxlet.2009.01.013. Epub 2009 Jan 20.

35.

EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis.

Mason RA, Morlock EV, Karagas MR, Kelsey KT, Marsit CJ, Schned AR, Andrew AS.

Carcinogenesis. 2009 Jul;30(7):1155-60. doi: 10.1093/carcin/bgp077. Epub 2009 Apr 16.

36.

Bladder cancer SNP panel predicts susceptibility and survival.

Andrew AS, Gui J, Sanderson AC, Mason RA, Morlock EV, Schned AR, Kelsey KT, Marsit CJ, Moore JH, Karagas MR.

Hum Genet. 2009 Jun;125(5-6):527-39. doi: 10.1007/s00439-009-0645-6. Epub 2009 Mar 1.

37.

Intraperitoneal India ink deposits appearing as endometriosis in a patient with chronic pelvic pain.

Algoe KK, Chen H, Schned AR, Whiteside JL.

Obstet Gynecol. 2008 Aug;112(2 Pt 2):448-50. doi: 10.1097/AOG.0b013e31816c484e.

PMID:
18669759
38.

Polyomavirus infection of the urinary tract presenting as hemorrhagic cystitis in an immunocompetent five-year-old boy.

Gonzalez JL, Balestra S, Schned AR, Gutmann EJ, Tsongalis GJ.

Diagn Cytopathol. 2008 Jun;36(6):375-8. doi: 10.1002/dc.20808.

PMID:
18478601
39.

Histological classification and stage of newly diagnosed bladder cancer in a population-based study from the Northeastern United States.

Schned AR, Andrew AS, Marsit CJ, Kelsey KT, Zens MS, Karagas MR.

Scand J Urol Nephrol. 2008;42(3):237-42. doi: 10.1080/00365590801948166.

40.

Survival following the diagnosis of noninvasive bladder cancer: WHO/International Society of Urological Pathology versus WHO classification systems.

Schned AR, Andrew AS, Marsit CJ, Zens MS, Kelsey KT, Karagas MR.

J Urol. 2007 Oct;178(4 Pt 1):1196-200; discussion 1200. Epub 2007 Aug 14.

PMID:
17698105
41.

Electrical impedance spectroscopy of the human prostate.

Halter RJ, Hartov A, Heaney JA, Paulsen KD, Schned AR.

IEEE Trans Biomed Eng. 2007 Jul;54(7):1321-7.

PMID:
17605363
42.

Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer.

Marsit CJ, Houseman EA, Schned AR, Karagas MR, Kelsey KT.

Carcinogenesis. 2007 Aug;28(8):1745-51. Epub 2007 May 23.

PMID:
17522068
43.

Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang.

Ernstoff MS, Crocenzi TS, Seigne JD, Crosby NA, Cole BF, Fisher JL, Uhlenhake JC, Mellinger D, Foster C, Farnham CJ, Mackay K, Szczepiorkowski ZM, Webber SM, Schned AR, Harris RD, Barth RJ Jr, Heaney JA, Noelle RJ.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):733s-740s. Review.

44.

Fatal relapse of ANCA-associated glomerulonephritis triggered by successive Epstein-Barr and varicella zoster virus infections.

Schned AR, Ornvold K, Tsongalis GJ, Chobanian MC.

Am J Kidney Dis. 2006 May;47(5):915-22. No abstract available.

PMID:
16632033
45.

Tumor-related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte-colony stimulating factor (GM-CSF).

Schwaab T, Tretter CP, Gibson JJ, Cole BF, Schned AR, Harris R, Fisher JL, Crosby N, Stempkowski LM, Heaney JA, Ernstoff MS.

Prostate. 2006 May 1;66(6):667-74.

PMID:
16425182
46.

Concordance of multiple analytical approaches demonstrates a complex relationship between DNA repair gene SNPs, smoking and bladder cancer susceptibility.

Andrew AS, Nelson HH, Kelsey KT, Moore JH, Meng AC, Casella DP, Tosteson TD, Schned AR, Karagas MR.

Carcinogenesis. 2006 May;27(5):1030-7. Epub 2005 Nov 25.

PMID:
16311243
47.

Real-time polymerase chain reaction and laser capture microdissection for the diagnosis of BK virus infection in renal allografts.

Adeyi OA, Belloni DR, Dufresne SD, Schned AR, Tsongalis GJ.

Am J Clin Pathol. 2005 Oct;124(4):537-42.

PMID:
16146816
48.

Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer.

Marsit CJ, Karagas MR, Andrew A, Liu M, Danaee H, Schned AR, Nelson HH, Kelsey KT.

Cancer Res. 2005 Aug 15;65(16):7081-5.

49.

Impaired cytolytic activity in peripheral blood T cells from renal cell carcinoma patients.

Crocenzi TS, Tretter CP, Schwaab T, Schned AR, Heaney JA, Cole BF, Fisher JL, Ernstoff MS.

Clin Immunol. 2005 Oct;117(1):6-11.

PMID:
16027041
50.

Occupation and bladder cancer risk in a population-based case-control study in New Hampshire.

Colt JS, Baris D, Stewart P, Schned AR, Heaney JA, Mott LA, Silverman D, Karagas M.

Cancer Causes Control. 2004 Oct;15(8):759-69.

PMID:
15456989

Supplemental Content

Loading ...
Support Center